Usnic acid

Name: Usnic acid
Brand: MedChemExpress
SKU: HY-N0656
Rating: 4.5 (1 reviews)

Cat. No.: HY-N0656 Purity: 98.90%: FAQs
Data Sheet
SDS

COA
Handling Instructions Technical Support

Usnic acid is a secondary metabolite of lichens with a unique dibenzofuran skeleton. Usnic acid inhibits DNA/RNA synthesis and has antibacterial activity. Usnic acid induces cell cycle arrest and apoptosis and has anticancer activity. Usnic acid inhibits RANKL-mediated osteoclast formation and function by reducing the transcriptional and translational expression of NFATc1. Usnic acid has antioxidant and anti-inflammatory activities by inhibiting lipid peroxidation and myeloperoxidase.

For research use only. We do not sell to patients.

Usnic acid Chemical Structure

CAS No. : 125-46-2

Size	Stock	Quantity
Free Sample (0.1 - 0.5 mg)	Apply Now
100 mg	In-stock	Estimated Time of Arrival: December 31
500 mg	In-stock	Estimated Time of Arrival: December 31
1 g	Get quote
5 g	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of Usnic acid:

(+)-Usnic acid Get quote
Usnic acid sodium Get quote

1 Publications Citing Use of MCE Usnic acid

•Preprints. 2024 Jan 4.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity
Purity & Documentation
References
Customer Review

Description

Cellular Effect

Cell Line	Type	Value	Description	References
HeLa	IC₅₀	> 10 μM Compound: (-)-1	Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 24 hrs by MTT assay Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 31282672]
HeLa	IC₅₀	> 10 μM Compound: (+)-1	Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 24 hrs by MTT assay Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 31282672]
HeLa	IC₅₀	> 10 μM Compound: (-)-1	Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 31282672]
HeLa	IC₅₀	10 μM Compound: (+)-1	Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 31282672]
MCF7	IC₅₀	> 10 μM Compound: (-)-1	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 24 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 31282672]
MCF7	IC₅₀	> 10 μM Compound: (+)-1	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 24 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 31282672]
MCF7	IC₅₀	> 10 μM Compound: (-)-1	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 31282672]
MCF7	IC₅₀	10 μM Compound: (+)-1	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 31282672]
PC-3	IC₅₀	> 10 μM Compound: (-)-1	Antiproliferative activity against human PC3 cells assessed as reduction in cell viability after 24 hrs by MTT assay Antiproliferative activity against human PC3 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 31282672]
PC-3	IC₅₀	> 10 μM Compound: (+)-1	Antiproliferative activity against human PC3 cells assessed as reduction in cell viability after 24 hrs by MTT assay Antiproliferative activity against human PC3 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 31282672]
PC-3	IC₅₀	> 10 μM Compound: (-)-1	Antiproliferative activity against human PC3 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human PC3 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 31282672]
PC-3	IC₅₀	> 10 μM Compound: (+)-1	Antiproliferative activity against human PC3 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human PC3 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 31282672]

In Vitro

Usnic acid (0-40 μg/mL, 0-150 min) inhibits the growth of B. subtilis, S. aureus and V. harveyi^[1].
Usnic acid (0.5/1 μg/mL, 15-150 min) inhibits the incorporation rate of DNA, RNA and protein synthesis macromolecular precursors thymidine, uridine and leucine in B. subtilis and S. aureus^[1].
Usnic acid (25-100 μM, 24-48 h) inhibits the viability and clonogenicity of A549 cells. It also induces G0/G1 cell cycle arrest, mitochondrial membrane depolarization and apoptosis of A549 cells^[2].
Usnic acid (0.3-3 μM, 4 d) inhibits the differentiation of bone marrow-derived macrophages (BMM) into mature osteoclasts in a dose-dependent manner^[4].
Usnic acid (3 μM, 0-3 d) inhibits the transcriptional and translational expression of RANKL on NFATc1 in BMMs^[4].
Usnic acid (3 μM, 5-30 min) inhibits RANKL-induced activities of MAP kinases p38, ERK and JNK in BMMs^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[2]

Cell Line:	A549 cells
Concentration:	25, 50, 100 μM
Incubation Time:	24/48 h
Result:	Inhibited cell proliferation (35-48%/59-72%).

Cell Proliferation Assay^[2]

Cell Line:	A549 cells
Concentration:	1, 5, 10 μM
Incubation Time:	7 days
Result:	Inhibited cell colony formation (8, 23, 85%).

Cell Cycle Analysis^[2]

Cell Line:	A549 cells
Concentration:	25, 50, 100 μM
Incubation Time:	24/48 h
Result:	Induced cell cycle arrest at G0/G1 (77%, 81% and 80%; 87%, 85%, and 82%). Down-regulated CDK4, CDK-6 and cyclin D1 protein levels. Up-regulated p21/Cip1 protein and cleaved-PARP levels.

Apoptosis Analysis^[2]

Cell Line:	A549 cells
Concentration:	25, 50, 100 μM
Incubation Time:	48 h
Result:	Increased the number of apoptotic cells (6%, 10% and 11%).

RT-PCR^[4]

Cell Line:	BMMs
Concentration:	Usnic acid (3 µM) for 1 h prior to RANKL (10 ng/mL) and M-CSF (30 ng/mL) stimulation
Incubation Time:	0, 1, 2, 3 d
Result:	Down-regulated the gene expression levels of TRAP, DC-STAMP, and cathepsin K.

Western Blot Analysis^[4]

Cell Line:	BMMs
Concentration:	Usnic acid (3 µM) for 1 h prior to RANKL (10 ng/mL) stimulation
Incubation Time:	5, 15, 30 min
Result:	Down-regulated the protein expression levels of p38, ERK and JNK.

In Vivo

Usnic acid (25-200 mg/kg, p.o., once) can inhibit Indomethacin (HY-14397)-induced gastric injury in rats (80.2-96.4%)^[3].
Usnic acid (1 μg/g, i.p., every day for up to 8 days) inhibited osteoclastic bone resorption in the lipopolysaccharide (LPS) bone erosion model ^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Indomethacin-induced gastric damage model (male, Albino-Wistar rats, weighing 180-190 g; Indomethacin 25 mg/kg body weight orally.)^[3]
Dosage:	25, 50, 100 and 200 mg/kg
Administration:	Oral gavage (p.o.), once
Result:	Reduced gastric damage in rats (80.2-96.4%). Increased SOD, GPx, GSH and cNOS levels. Reduced CAT, GR, LPO, iNOS and MPx levels.

Animal Model:	LPS-induced mouse bone erosion model (five-week-old male ICR mice, 5 µg/µL LPS was injected intraperitoneally on days 1 and 4)^[4]
Dosage:	1 μg/g
Administration:	Intraperitoneal injection (i.p.), every day for up to 8 days
Result:	Increased BMD and BV/TV. Reduced BS/TV and Tb.Sp.

Molecular Weight

344.32

Formula

C₁₈H₁₆O₇

CAS No.

125-46-2

Appearance

Solid

Color

White to yellow

SMILES

O=C(C1(C)C(OC2=C(C(C)=O)C(O)=C(C)C(O)=C12)=C3)C(C(C)=O)C3=O

Structure Classification

Others

Initial Source

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 3.33 mg/mL (9.67 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.9043 mL	14.5214 mL	29.0428 mL
5 mM	0.5809 mL	2.9043 mL	5.8085 mL
10 mM	---	---	---

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 50% PEG300 50% Saline
Solubility: 2 mg/mL (5.81 mM); Suspended solution; Need ultrasonic
Protocol 2

Add each solvent one by one: 0.5% CMC-Na/saline water
Solubility: 2 mg/mL (5.81 mM); Suspended solution; Need ultrasonic
Protocol 3

Add each solvent one by one: 15% Solutol HS 15 10% Cremophor EL 35% PEG400 40% Water
Solubility: 9.8 mg/mL (28.46 mM); Suspended solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Calculation results:

Working solution concentration: mg/mL

Purity & Documentation

Purity: 98.90%

Select Batch:

Data Sheet (290 KB) SDS (393 KB)

COA (259 KB) HNMR (251 KB) RP-HPLC (261 KB) LCMS (97 KB)

Handling Instructions (2659 KB)

References

[1]. Maciąg-Dorszyńska M, et al. Antibacterial activity of lichen secondary metabolite usnic acid is primarily caused by inhibition of RNA and DNA synthesis. FEMS Microbiol Lett. 2014 Apr;353(1):57-62. [Content Brief]

[2]. Singh N, et al. Usnic acid inhibits growth and induces cell cycle arrest and apoptosis in human lung carcinoma A549 cells. Nutr Cancer. 2013;65 Suppl 1:36-43. [Content Brief]

[3]. Odabasoglu F, et al. Gastroprotective and antioxidant effects of usnic acid on indomethacin-induced gastric ulcer in rats. J Ethnopharmacol. 2006 Jan 3;103(1):59-65. [Content Brief]

[4]. Kim KJ, et al. Effect of Usnic Acid on Osteoclastogenic Activity. J Clin Med. 2018 Oct 12;7(10):345. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.9043 mL	14.5214 mL	29.0428 mL	72.6069 mL
DMSO	5 mM	0.5809 mL	2.9043 mL	5.8086 mL	14.5214 mL

Usnic acid Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Usnic acid125-46-2BacterialDNA/RNA SynthesisNuclear Factor of activated T Cells (NFAT)ApoptosisAntibacterialAnticancerB. subtilisS. aureusA549 cellsBMMsIndomethacin-induced gastric damage modelLPS-induced mouse bone erosion modelInhibitorinhibitorinhibit

Your Recently Viewed Products:

Product Name

Requested Quantity *

Applicant Name *

Salutation

Email Address *

Phone Number *

Department

Organization Name *

City

State

Country or Region *

Remarks

Product Name

Lot #

Applicant Name *

Email Address *

Phone Number

Department *

Organization Name *

Country or Region *

Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

Usnic acid

Customer Review

Other Forms of Usnic acid:

Usnic acid Related Antibodies

1 Publications Citing Use of MCE Usnic acid

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity

Purity & Documentation

References

Customer Review

Usnic acid Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Usnic acid Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report